一种新的疟疾药物GanLum在12个非洲国家的审判中治愈了97.4%的病例,对抗药性菌株很有希望。 A new malaria drug, GanLum, cured 97.4% of cases in trials across 12 African nations and shows promise against resistant strains.

由诺华公司和合作伙伴开发的新型疟疾治疗GanLum在12个非洲国家的第三阶段试验中实现了97.4%的治愈率,表明对抗药菌株,包括抗青蒿素寄生虫的抗药性有效。 A new malaria treatment, GanLum, developed by Novartis and partners, achieved a 97.4% cure rate in a Phase III trial across 12 African countries, showing effectiveness against drug-resistant strains, including artemisinin-resistant parasites. 这种药物结合了甘蓝白剂——一种具有独特机制的新型化合物——和一种新的乳液制剂,针对多种寄生虫形式,并可能减少传播。 The drug, combining ganaplacide—a novel compound with a unique mechanism—and a new formulation of lumefantrine, targets multiple parasite forms and may reduce transmission. 专家称这是自1999年以来疟疾治疗方面取得的第一个重大进展,预期在大约16个月后将获得管制批准,到2027年有可能获得。 Experts call it the first major advance in malaria treatment since 1999, with regulatory approval expected in about 16 months and potential availability by 2027.